Literature DB >> 34253859

Hepatitis B virus evades immune recognition via RNA adenosine deaminase ADAR1-mediated viral RNA editing in hepatocytes.

Liyuan Wang1,2, Yang Sun1,2, Xiaojia Song1,2, Zehua Wang1,2, Yankun Zhang1,2, Ying Zhao1,2, Xueqi Peng1,2, Xiaodong Zhang1,2, Chunyang Li1,2,3, Chengjiang Gao1,2,3,4, Nailin Li5, Lifen Gao1,2,3, Xiaohong Liang1,2,3, Zhuanchang Wu6,7, Chunhong Ma8,9,10,11.   

Abstract

HBV is considered as a "stealth" virus that does not invoke interferon (IFN) responses; however, the mechanisms by which HBV bypasses innate immune recognition are poorly understood. In this study, we identified adenosine deaminases acting on RNA 1 (ADAR1), which is a key factor in HBV evasion from IFN responses in hepatocytes. Mechanically, ADAR1 interacted with HBV RNAs and deaminated adenosine (A) to generate inosine (I), which disrupted host immune recognition and thus promoted HBV replication. Loss of ADAR1 or its deficient deaminase activity promoted IFN responses and inhibited HBV replication in hepatocytes, and blocking the IFN signaling pathways released the inhibition of HBV replication caused by ADAR1 deficiency. Notably, the HBV X protein (HBx) transcriptionally promoted ADAR1 expression to increase the threshold required to trigger intrinsic immune activation, which in turn enhanced HBV escape from immune recognition, leading to persistent infection. Supplementation with 8-azaadenosine, an ADAR1 inhibitor, efficiently enhanced liver immune activation to promote HBV clearance in vivo and in vitro. Taken together, our results delineate a molecular mechanism by which HBx promotes ADAR1-derived HBV immune escape and suggest a targeted therapeutic intervention for HBV infection.
© 2021. The Author(s), under exclusive licence to CSI and USTC.

Entities:  

Keywords:  ADAR1; HBV replication; HBx; IFN response; RNA editing

Mesh:

Substances:

Year:  2021        PMID: 34253859      PMCID: PMC8322072          DOI: 10.1038/s41423-021-00729-1

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   22.096


  48 in total

1.  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

Authors:  Xiaoming Cheng; Yuchen Xia; Elisavet Serti; Peter Daniel Block; Michelle Chung; Kazuaki Chayama; Barbara Rehermann; T Jake Liang
Journal:  Hepatology       Date:  2017-12       Impact factor: 17.425

2.  The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly.

Authors:  Hiromichi Dansako; Youki Ueda; Nobuaki Okumura; Shinya Satoh; Masaya Sugiyama; Masashi Mizokami; Masanori Ikeda; Nobuyuki Kato
Journal:  FEBS J       Date:  2015-11-09       Impact factor: 5.542

3.  The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.

Authors:  Seiichi Sato; Kai Li; Takeshi Kameyama; Takaya Hayashi; Yuji Ishida; Shuko Murakami; Tsunamasa Watanabe; Sayuki Iijima; Yu Sakurai; Koichi Watashi; Susumu Tsutsumi; Yusuke Sato; Hidetaka Akita; Takaji Wakita; Charles M Rice; Hideyoshi Harashima; Michinori Kohara; Yasuhito Tanaka; Akinori Takaoka
Journal:  Immunity       Date:  2014-12-18       Impact factor: 31.745

4.  The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein.

Authors:  Congwen Wei; Caifei Ni; Ting Song; Yu Liu; XiaoLi Yang; Zirui Zheng; Yongxia Jia; Yuan Yuan; Kai Guan; Yang Xu; Xiaozhong Cheng; Yanhong Zhang; Xiao Yang; Youliang Wang; Chaoyang Wen; Qing Wu; Wei Shi; Hui Zhong
Journal:  J Immunol       Date:  2010-06-16       Impact factor: 5.422

5.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  Genomic analysis of the host response to hepatitis B virus infection.

Authors:  Stefan Wieland; Robert Thimme; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-20       Impact factor: 11.205

7.  Early inhibition of hepatocyte innate responses by hepatitis B virus.

Authors:  Souphalone Luangsay; Marion Gruffaz; Nathalie Isorce; Barbara Testoni; Maud Michelet; Suzanne Faure-Dupuy; Sarah Maadadi; Malika Ait-Goughoulte; Romain Parent; Michel Rivoire; Hassan Javanbakht; Julie Lucifora; David Durantel; Fabien Zoulim
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

Review 8.  Control of viral transcripts as a concept for future HBV therapies.

Authors:  Christoph Seeger
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

9.  HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.

Authors:  Pascal Mutz; Philippe Metz; Florian A Lempp; Silke Bender; Bingqian Qu; Katrin Schöneweis; Stefan Seitz; Thomas Tu; Agnese Restuccia; Jamie Frankish; Christopher Dächert; Benjamin Schusser; Ronald Koschny; Georgios Polychronidis; Peter Schemmer; Katrin Hoffmann; Thomas F Baumert; Marco Binder; Stephan Urban; Ralf Bartenschlager
Journal:  Gastroenterology       Date:  2018-02-01       Impact factor: 22.682

10.  Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection.

Authors:  Martin K Thomsen; Ramya Nandakumar; Daniela Stadler; Antje Malo; Roser Marin Valls; Fan Wang; Line S Reinert; Frederik Dagnaes-Hansen; Anne Kruse Hollensen; Jacob Giehm Mikkelsen; Ulrike Protzer; Søren R Paludan
Journal:  Hepatology       Date:  2016-07-26       Impact factor: 17.425

View more
  6 in total

1.  Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization.

Authors:  Qi Zhang; Bingqiu Xiu; Liyi Zhang; Ming Chen; Weiru Chi; Lun Li; Rong Guo; Jingyan Xue; Benlong Yang; Xiaoyan Huang; Zhi-Ming Shao; Shenglin Huang; Yayun Chi; Jiong Wu
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

Review 2.  Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review.

Authors:  Enakshi Sivasudhan; Neil Blake; Zhiliang Lu; Jia Meng; Rong Rong
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

3.  LINC01431 Promotes Histone H4R3 Methylation to Impede HBV Covalently Closed Circular DNA Transcription by Stabilizing PRMT1.

Authors:  Yang Sun; Yan Teng; Liyuan Wang; Zhaoying Zhang; ChaoJia Chen; Yingchun Wang; Xiaodong Zhang; Peng Xiang; Xiaojia Song; Jinghui Lu; Nailin Li; Lifen Gao; Xiaohong Liang; Yuchen Xia; Zhuanchang Wu; Chunhong Ma
Journal:  Adv Sci (Weinh)       Date:  2022-04-10       Impact factor: 17.521

4.  Genome-Wide Identification and Characterization of RNA/DNA Differences Associated with Drought Response in Wheat.

Authors:  Yan Pan; Mengqi Li; Jiaqian Huang; Wenqiu Pan; Tingrui Shi; Qifan Guo; Guang Yang; Xiaojun Nie
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 5.  Regulation of Pattern-Recognition Receptor Signaling by HBX During Hepatitis B Virus Infection.

Authors:  Hongjuan You; Suping Qin; Fulong Zhang; Wei Hu; Xiaocui Li; Dongsheng Liu; Fanyun Kong; Xiucheng Pan; Kuiyang Zheng; Renxian Tang
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 6.  The impact of RNA modifications on the biology of DNA virus infection.

Authors:  Suba Rajendren; John Karijolich
Journal:  Eur J Cell Biol       Date:  2022-05-21       Impact factor: 6.020

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.